ETV2

Summary

ETV2 (ETS variant transcription factor 2, HGNC:3491) is a protein-coding gene on chromosome 19q13.12, encoding ETS translocation variant 2 (O00321). Binds to DNA sequences containing the consensus pentanucleotide 5’-CGGA[AT]-3'.

Enables sequence-specific double-stranded DNA binding activity. Predicted to be involved in cell differentiation and regulation of transcription by RNA polymerase II. Predicted to act upstream of or within several processes, including cell surface receptor signaling pathway; positive regulation of endothelial cell differentiation; and positive regulation of macromolecule biosynthetic process. Predicted to be active in nucleus. Implicated in limb ischemia.

Source: NCBI Gene 2116 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Limited, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 61 total — 2 likely-pathogenic
• Phenotypes (HPO): 1
• MANE Select transcript: NM_014209

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3491
Approved symbol	ETV2
Name	ETS variant transcription factor 2
Location	19q13.12
Locus type	gene with protein product
Status	Approved
Aliases	ER71
Ensembl gene	ENSG00000105672
Ensembl biotype	protein_coding
OMIM	609358
Entrez	2116

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000379023, ENST00000379026, ENST00000402764, ENST00000403402, ENST00000479824, ENST00000591135

RefSeq mRNA: 3 — MANE Select: NM_014209 NM_001300974, NM_001304549, NM_014209

CCDS: CCDS32995, CCDS74341, CCDS77281

Canonical transcript exons

ENST00000402764 — 7 exons

Exon	Start	End
ENSE00001479545	35641745	35642156
ENSE00002801373	35644652	35644871
ENSE00002865310	35644235	35644347
ENSE00003508542	35642965	35643045
ENSE00003629362	35642615	35642698
ENSE00003891325	35642434	35642530
ENSE00003892535	35643274	35643753

Expression profiles

Bgee: expression breadth ubiquitous, 160 present calls, max score 81.19.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 2.3258 / max 75.7823, expressed in 1321 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
175360	2.0569	1242
175359	0.2689	92

Top tissues by expression

290 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	81.19	gold quality
right testis	UBERON:0004534	80.29	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.15	gold quality
testis	UBERON:0000473	77.98	gold quality
mucosa of transverse colon	UBERON:0004991	72.55	gold quality
stromal cell of endometrium	CL:0002255	70.83	gold quality
cervix squamous epithelium	UBERON:0006922	70.81	gold quality
granulocyte	CL:0000094	68.88	gold quality
lower esophagus mucosa	UBERON:0035834	68.74	gold quality
right lobe of liver	UBERON:0001114	68.67	gold quality
esophagus mucosa	UBERON:0002469	68.46	gold quality
skin of abdomen	UBERON:0001416	67.58	gold quality
body of pancreas	UBERON:0001150	67.52	gold quality
skin of leg	UBERON:0001511	67.48	gold quality
right adrenal gland	UBERON:0001233	66.78	gold quality
left adrenal gland	UBERON:0001234	66.45	gold quality
sperm	CL:0000019	66.38	silver quality
left adrenal gland cortex	UBERON:0035825	66.11	gold quality
right adrenal gland cortex	UBERON:0035827	65.38	gold quality
zone of skin	UBERON:0000014	65.37	gold quality
male germ cell	CL:0000015	65.17	silver quality
cortical plate	UBERON:0005343	65.14	gold quality
adrenal cortex	UBERON:0001235	64.44	gold quality
cervix epithelium	UBERON:0004801	64.30	gold quality
ectocervix	UBERON:0012249	64.29	gold quality
uterine cervix	UBERON:0000002	63.13	gold quality
body of stomach	UBERON:0001161	62.90	gold quality
endocervix	UBERON:0000458	62.78	gold quality
esophagus	UBERON:0001043	62.75	gold quality
transverse colon	UBERON:0001157	62.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.92

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

9 targets.

Target	Regulation
ETV2
FLI1	Activation
KDR
LMO2
MMP1	Activation
PRKACA
SOX9	Activation
SPI1	Activation
TEK	Unknown

Upstream regulators (CollecTRI, top): CREB1, ETV2, NKX2-5, SOX9, SP1, SRY, TAL1

Literature-anchored findings (GeneRIF, showing 21)

• identify human Etv2/ER71 and mouse ER71 proteins as functional orthologs of Etsrp (PMID:18270322)
• ets variant 2 (ETV2) alone directly converts primary human adult skin fibroblasts into functional vascular endothelial cells. (PMID:25540418)
• Single-factor ETV2 transduction successfully reprogrammed dermal fibroblasts into functional EPCs. (PMID:27488544)
• ETV2 alone can directly reprogram postnatal cells to functional, mature endothelial cells. (PMID:28003219)
• REVIEW. the interplay among the ETS transcription factor ETV2, vascular endothelial growth factor, and its receptor VEGFR2/FLK1 is essential for hematopoietic and vascular development. Emerging studies also support the role of these three factors and possible interplay in hematopoietic and vascular regeneration. (PMID:28026128)
• ETS transcription factor Etv2, a critical factor for haematopoietic and vascular development, is also required for haematopoietic regeneration. Etv2, which is silent in homeostatic HSCs, was transiently activated in regenerating HSPCs and was required for the HSC expansion and regeneration following bone marrow transplantation or haematopoietic injury. (PMID:29697486)
• among the many factors wired within this complex regulatory network, ETV2, SCL and RUNX1 are the central components. All three factors are absolutely required for blood cell generation, each one controlling a precise step of specification from the mesoderm germ layer to fully functional blood progenitors (PMID:31432499)
• ETV2/ER71 Transcription Factor as a Therapeutic Vehicle for Cardiovascular Disease. (PMID:31534512)
• These findings provide insight into the novel molecular mechanisms of ETV2 function in regulating cardiovascular lineage development from mouse embryonic stem cells. (PMID:31744543)
• Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA. (PMID:32832668)
• FGF primes angioblast formation by inducing ETV2 and LMO2 via FGFR1/BRAF/MEK/ERK. (PMID:32910224)
• Biallelic variants in ETV2 in a family with congenital heart defects, vertebral abnormalities and preaxial polydactyly. (PMID:33359164)
• Upregulation of ETV2 Expression Promotes Endothelial Differentiation of Human Dental Pulp Stem Cells. (PMID:33522307)
• Morphological characterization of Etv2 vascular explants using fractal analysis and atomic force microscopy. (PMID:34146583)
• ETV2 regulates PARP-1 binding protein to induce ER stress-mediated death in tuberin-deficient cells. (PMID:35181635)
• A 3-Gene Random Forest Model to Diagnose Non-obstructive Azoospermia Based on Transcription Factor-Related Henes. (PMID:35715550)
• ETV2 promotes osteogenic differentiation of human dental pulp stem cells through the ERK/MAPK and PI3K-Akt signaling pathways. (PMID:36195958)
• ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming. (PMID:36927793)
• ETV2 primes hematoendothelial gene enhancers prior to hematoendothelial fate commitment. (PMID:37330911)
• SOX17/ETV2 improves the direct reprogramming of adult fibroblasts to endothelial cells. (PMID:38503291)
• BCL6B-dependent suppression of ETV2 hampers endothelial cell differentiation. (PMID:39075623)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Etv2	ENSMUSG00000006311
rattus_norvegicus	Etv2	ENSRNOG00000024288

Paralogs (28): ETV1 (ENSG00000006468), ETV7 (ENSG00000010030), SPI1 (ENSG00000066336), ELF4 (ENSG00000102034), ERF (ENSG00000105722), ELF2 (ENSG00000109381), ELK3 (ENSG00000111145), ETV3 (ENSG00000117036), ELF1 (ENSG00000120690), SPDEF (ENSG00000124664), ELK1 (ENSG00000126767), ETS1 (ENSG00000134954), EHF (ENSG00000135373), ELF5 (ENSG00000135374), ETV6 (ENSG00000139083), FLI1 (ENSG00000151702), GABPA (ENSG00000154727), ERG (ENSG00000157554), ETS2 (ENSG00000157557), ELK4 (ENSG00000158711), ELF3 (ENSG00000163435), FEV (ENSG00000163497), SPIC (ENSG00000166211), ETV4 (ENSG00000175832), ETV5 (ENSG00000244405), ETV3L (ENSG00000253831), ERFL (ENSG00000268041), SPIB (ENSG00000269404)

Protein

Protein identifiers

ETS translocation variant 2 — O00321 (reviewed: O00321)

Alternative names: Ets-related protein 71

All UniProt accessions (4): O00321, K7ERX2, Q3KNT2, S4R454

UniProt curated annotations — full annotation on UniProt →

Function. Binds to DNA sequences containing the consensus pentanucleotide 5’-CGGA[AT]-3'.

Subcellular location. Nucleus.

Similarity. Belongs to the ETS family.

Isoforms (2)

UniProt ID	Names	Canonical?
O00321-1	1	yes
O00321-2	2

RefSeq proteins (3): NP_001287903, NP_001291478, NP_055024* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000418	Ets_dom	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR046328	ETS_fam	Family

Pfam: PF00178

UniProt features (6 total): sequence conflict 2, chain 1, DNA-binding region 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O00321-F1	57.35	0.24

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 110 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_ENDOTHELIAL_CELL_DIFFERENTIATION, GOBP_FORMATION_OF_PRIMARY_GERM_LAYER, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOBP_REGULATION_OF_ENDOTHELIAL_CELL_DIFFERENTIATION, GOBP_REGULATION_OF_EPITHELIAL_CELL_DIFFERENTIATION, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_REGULATION_OF_MESODERM_DEVELOPMENT, GOBP_POSITIVE_REGULATION_OF_CELL_DIFFERENTIATION, GOBP_BLOOD_VESSEL_MORPHOGENESIS, GOBP_ENDOTHELIUM_DEVELOPMENT

GO Biological Process (18): blastocyst development (GO:0001824), placenta development (GO:0001890), regulation of transcription by RNA polymerase II (GO:0006357), Notch signaling pathway (GO:0007219), mesodermal cell fate specification (GO:0007501), positive regulation of gene expression (GO:0010628), Wnt signaling pathway (GO:0016055), cell differentiation (GO:0030154), erythrocyte differentiation (GO:0030218), BMP signaling pathway (GO:0030509), positive regulation of endothelial cell differentiation (GO:0045603), blood vessel morphogenesis (GO:0048514), positive regulation of mesoderm development (GO:2000382), in utero embryonic development (GO:0001701), mesoderm formation (GO:0001707), regulation of DNA-templated transcription (GO:0006355), hemopoiesis (GO:0030097), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (7): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), sequence-specific double-stranded DNA binding (GO:1990837), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of DNA-templated transcription	2
transcription by RNA polymerase II	2
cell surface receptor signaling pathway	2
regulation of gene expression	2
regulation of transcription by RNA polymerase II	2
in utero embryonic development	1
anatomical structure development	1
animal organ development	1
cell fate specification	1
mesodermal cell fate commitment	1
gene expression	1
positive regulation of macromolecule biosynthetic process	1
cellular developmental process	1
myeloid cell differentiation	1
erythrocyte homeostasis	1
cellular response to BMP stimulus	1
transforming growth factor beta receptor superfamily signaling pathway	1
positive regulation of epithelial cell differentiation	1
endothelial cell differentiation	1
regulation of endothelial cell differentiation	1
blood vessel development	1
tube morphogenesis	1
mesoderm development	1
positive regulation of developmental process	1
regulation of mesoderm development	1
chordate embryonic development	1
formation of primary germ layer	1
mesoderm morphogenesis	1
DNA-templated transcription	1
regulation of RNA biosynthetic process	1
cell development	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
double-stranded DNA binding	1

Protein interactions and networks

STRING

684 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ETV2	GATA2	P23769	730
ETV2	TAL1	P17542	632
ETV2	LMO2	P25791	604
ETV2	MMP1	P03956	601
ETV2	CDH5	P33151	601
ETV2	KDR	P35968	594
ETV2	FOXC2	Q99958	546
ETV2	SOX7	Q9BT81	522
ETV2	PECAM1	P16284	512
ETV2	CLEC14A	Q86T13	500
ETV2	SOX17	Q9H6I2	492
ETV2	TEK	Q02763	481
ETV2	NKX2-5	P52952	469
ETV2	MYL7	Q01449	457
ETV2	SOX18	P35713	456

IntAct

2 interactions, top by confidence:

A	B	Type	Score
ETV2	TFRC	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (4): TFRC (Proximity Label-MS), KDM3A (Affinity Capture-Western), KDM3A (Reconstituted Complex), ETV2 (Reconstituted Complex)

ESM2 similar proteins: A1YGK1, A2T7E6, A8MZG2, A9YTQ3, O00321, O08574, O43593, O43638, O75593, O88621, P0C1T1, P0DV77, P14652, P19419, P41163, P43688, P46099, P70368, P97609, Q13351, Q32LE6, Q3B7M4, Q3ZBG8, Q5R638, Q5TM83, Q61574, Q61645, Q61660, Q63247, Q6KAU7, Q6NUN9, Q6ZN32, Q80Z64, Q86Y26, Q8BZ34, Q8BZW2, Q8CGW9, Q8IUC6, Q8IXT2, Q8NDX1

Diamond homologs: A0A1W2PQ73, A0JN51, A1A4L6, A1YF15, A1YG61, A1YG91, A2D4Z7, A2T737, A2T762, A3FEM2, A4GTP4, A8WFJ9, O00321, O01519, O70132, O70273, O95238, P01105, P10157, P11308, P11536, P13474, P14921, P15036, P15037, P15062, P18755, P18756, P19102, P19419, P20105, P26323, P27577, P28322, P28324, P29773, P29774, P29775, P29776, P32519

SIGNOR signaling

4 interactions.

A	Effect	B	Mechanism
ETV2	“up-regulates quantity by expression”	FLI1	“transcriptional regulation”
ETV2	“up-regulates quantity by expression”	SPI1	“transcriptional regulation”
GATA2	“up-regulates activity”	ETV2	binding
ETV2	up-regulates	Differentiation

Disease & clinical

Clinical variants and AI predictions

ClinVar

61 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	2
Uncertain significance	54
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
1162783	NM_014209.4(ETV2):c.757G>T (p.Asp253Tyr)	Likely pathogenic
1162784	NM_014209.4(ETV2):c.350del (p.Gly117fs)	Likely pathogenic

SpliceAI

666 predictions. Top by Δscore:

Variant	Effect	Δscore
19:35642497:G:GT	donor_gain	1.0000
19:35642511:G:T	donor_gain	1.0000
19:35642525:GGC:G	donor_gain	1.0000
19:35644226:A:AG	acceptor_gain	1.0000
19:35644227:T:G	acceptor_gain	1.0000
19:35644233:A:AG	acceptor_gain	1.0000
19:35644233:AG:A	acceptor_gain	1.0000
19:35644234:G:GA	acceptor_gain	1.0000
19:35644234:GG:G	acceptor_gain	1.0000
19:35644234:GGT:G	acceptor_gain	1.0000
19:35644234:GGTC:G	acceptor_gain	1.0000
19:35644234:GGTCC:G	acceptor_gain	1.0000
19:35644329:GCT:G	donor_gain	1.0000
19:35644345:GAG:G	donor_gain	1.0000
19:35642497:G:T	donor_gain	0.9900
19:35642695:A:T	donor_gain	0.9900
19:35642719:C:CG	donor_gain	0.9900
19:35642719:C:G	donor_gain	0.9900
19:35642734:G:GT	donor_gain	0.9900
19:35642742:G:GT	donor_gain	0.9900
19:35643027:G:GT	donor_gain	0.9900
19:35644226:ATCCC:A	acceptor_gain	0.9900
19:35644230:C:A	acceptor_gain	0.9900
19:35644330:C:G	donor_gain	0.9900
19:35644343:AAGAG:A	donor_loss	0.9900
19:35644344:AGAGG:A	donor_loss	0.9900
19:35644345:G:GT	donor_gain	0.9900
19:35644345:GAGG:G	donor_loss	0.9900
19:35644346:AGGTG:A	donor_loss	0.9900
19:35644347:GG:G	donor_loss	0.9900

AlphaMissense

2188 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
19:35644324:T:C	F269L	1.000
19:35644325:T:C	F269S	1.000
19:35644326:C:A	F269L	1.000
19:35644326:C:G	F269L	1.000
19:35644255:T:C	F246L	0.999
19:35644256:T:C	F246S	0.999
19:35644257:C:A	F246L	0.999
19:35644257:C:G	F246L	0.999
19:35644305:G:C	W262C	0.999
19:35644305:G:T	W262C	0.999
19:35644325:T:G	F269C	0.999
19:35644666:G:C	W281C	0.999
19:35644666:G:T	W281C	0.999
19:35644249:T:A	W244R	0.998
19:35644249:T:C	W244R	0.998
19:35644251:G:C	W244C	0.998
19:35644251:G:T	W244C	0.998
19:35644303:T:A	W262R	0.998
19:35644303:T:C	W262R	0.998
19:35644664:T:A	W281R	0.998
19:35644664:T:C	W281R	0.998
19:35644692:T:C	M290T	0.998
19:35644693:G:A	M290I	0.998
19:35644693:G:C	M290I	0.998
19:35644693:G:T	M290I	0.998
19:35644781:T:C	F320L	0.998
19:35644783:C:A	F320L	0.998
19:35644783:C:G	F320L	0.998
19:35644678:G:C	K285N	0.997
19:35644678:G:T	K285N	0.997

dbSNP variants (sampled 300 via entrez): RS1000151679 (19:35640711 G>A), RS1000248813 (19:35645030 T>C), RS1000249590 (19:35644869 C>A,G), RS1000766937 (19:35640817 CATGT>C,CATGTATGT), RS1001311370 (19:35643539 C>A,T), RS1002270989 (19:35640245 G>A), RS1002719757 (19:35642085 C>A), RS1003218371 (19:35643308 C>G), RS1003313784 (19:35640780 T>C), RS1003671042 (19:35640946 A>C), RS1004198304 (19:35642494 C>G,T), RS1004314092 (19:35642937 C>A,G), RS1004594773 (19:35641148 C>T), RS1004666766 (19:35639821 C>T), RS1005051922 (19:35640856 TTTG>T)

Disease associations

OMIM: gene MIM:609358 | disease phenotypes: MIM:241550, MIM:603596

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Limited	Autosomal recessive

Mondo (3): hypoplastic left heart syndrome (MONDO:0004933), polydactyly (MONDO:0021003), congenital heart disease (MONDO:0005453)

Orphanet (1): Hypoplastic left heart syndrome (Orphanet:2248)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0010442	Polydactyly

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST010703_277	Brain morphology (MOSTest)	2.000000e-15

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0004346	neuroimaging measurement

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400
D018636	Hypoplastic Left Heart Syndrome	C14.240.400.625; C14.280.400.625; C16.131.240.400.625
D017689	Polydactyly	C05.660.585.600; C16.131.621.585.600

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, affects cotreatment, decreases expression, decreases reaction, increases expression	2
sotorasib	increases expression, affects cotreatment	1
bisphenol A	increases expression	1
nickel sulfate	increases expression	1
tert-butylphenyl diphenyl phosphate	affects cotreatment, decreases expression, decreases reaction, increases expression	1
CGP 52608	affects binding, increases reaction	1
jinfukang	increases expression	1
trametinib	affects cotreatment, increases expression	1
NVP-BKM120	affects cotreatment, increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Digitonin	increases expression, affects cotreatment, decreases expression, decreases reaction	1
Chlorpyrifos	affects cotreatment, decreases expression, decreases reaction, increases expression	1
Fluorouracil	affects cotreatment, decreases expression, decreases reaction, increases expression	1
Mercuric Chloride	affects cotreatment, decreases expression, decreases reaction, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Copper Sulfate	decreases expression	1
Particulate Matter	decreases expression, increases abundance	1

Cellosaurus cell lines

4 cell lines: 4 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1N1	SEES3-1V human ETV2, clone1	Embryonic stem cell	Male
CVCL_A1N2	SEES3-1V human ETV2, clone2	Embryonic stem cell	Male
CVCL_A1N3	SEES3-1V human ETV2, clone3	Embryonic stem cell	Male
CVCL_C4RV	WAe009-A-92	Embryonic stem cell	Female

Clinical trials (associated diseases)

351 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT02781922	PHASE3	RECRUITING	Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function